Free Trial

Enovis Q2 2024 Earnings Report

Enovis logo
$32.52 -1.27 (-3.76%)
As of 04/4/2025 03:59 PM Eastern

Enovis EPS Results

Actual EPS
$0.62
Consensus EPS
$0.59
Beat/Miss
Beat by +$0.03
One Year Ago EPS
$0.61

Enovis Revenue Results

Actual Revenue
$525.20 million
Expected Revenue
$525.99 million
Beat/Miss
Missed by -$790.00 thousand
YoY Revenue Growth
+22.60%

Enovis Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Enovis Earnings Headlines

Needham & Company LLC Reiterates Buy Rating for Enovis (NYSE:ENOV)
Thinking of buying Nvidia? Read this first
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Enovis backs Q1 revenue view $555M-$563M, consensus $558.79M
See More Enovis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enovis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enovis and other key companies, straight to your email.

About Enovis

Enovis (NYSE:ENOV) operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

View Enovis Profile

More Earnings Resources from MarketBeat